TRCT
KYTX icon

Tower Research Capital (TRC)’s Kyverna Therapeutics KYTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21K Sell
2,353
-775
-25% -$6.88K ﹤0.01% 3514
2026
Q1 		$27K Sell
3,128
-1,945
-38% -$16.2K ﹤0.01% 3265
2025
Q4 		$47.7K Sell
5,073
-1,158
-19% -$8.6K ﹤0.01% 2454
2025
Q3 		$37.4K Sell
6,231
-4,675
-43% -$18.7K ﹤0.01% 2751
2025
Q2 		$33.5K Buy
10,906
+2,733
+33% +$6.76K ﹤0.01% 3319
2025
Q1 		$15.8K Buy
8,173
+5,431
+198% +$16K ﹤0.01% 3205
2024
Q4 		$10.3K Sell
2,742
-10,107
-79% -$48.4K ﹤0.01% 3819
2024
Q3 		$62.8K Buy
+12,849
New +$99.1K ﹤0.01% 2586
2024
Q2 		– Sell
-766
Closed -$19K – 6057
2024
Q1 		$19K Buy
+766
New +$21.4K ﹤0.01% 3047

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Tower Research Capital (TRC)'s KYTX Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Kyverna Therapeutics (KYTX) stake by 25% in Q2 2026, selling an estimated $6.88K and leaving 2,353 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #3514.

Tower Research Capital (TRC) first reported a position in KYTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $62.8K in Q3 2024. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Tower Research Capital (TRC) held 2,353 shares of Kyverna Therapeutics worth $21K as of Q2 2026.
  • Tower Research Capital (TRC) sold 775 Kyverna Therapeutics shares in Q2 2026, an estimated $6.88K.
  • Kyverna Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3514 holding.
  • Tower Research Capital (TRC) first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Tower Research Capital (TRC)'s Kyverna Therapeutics position peaked at $62.8K in Q3 2024.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.